Heck Capital Advisors LLC Raises Position in Abbott Laboratories $ABT

Heck Capital Advisors LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 7.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,532 shares of the healthcare product maker’s stock after purchasing an additional 326 shares during the period. Heck Capital Advisors LLC’s holdings in Abbott Laboratories were worth $616,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the period. Congress Asset Management Co. lifted its holdings in Abbott Laboratories by 6.3% in the first quarter. Congress Asset Management Co. now owns 3,529 shares of the healthcare product maker’s stock valued at $468,000 after acquiring an additional 210 shares during the period. RDA Financial Network purchased a new stake in shares of Abbott Laboratories during the 1st quarter worth $204,000. Miracle Mile Advisors LLC grew its stake in shares of Abbott Laboratories by 6.4% during the 1st quarter. Miracle Mile Advisors LLC now owns 38,122 shares of the healthcare product maker’s stock worth $5,057,000 after purchasing an additional 2,293 shares during the period. Finally, Capital Investment Advisors LLC increased its holdings in shares of Abbott Laboratories by 5.3% in the 1st quarter. Capital Investment Advisors LLC now owns 22,737 shares of the healthcare product maker’s stock valued at $3,016,000 after purchasing an additional 1,137 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada upped their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Tuesday, July 15th. Leerink Partners began coverage on Abbott Laboratories in a report on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective for the company. Jefferies Financial Group upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their target price for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $145.39.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.7%

Shares of NYSE:ABT opened at $133.63 on Tuesday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $232.58 billion, a P/E ratio of 16.75, a P/E/G ratio of 2.55 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The stock’s fifty day simple moving average is $132.08 and its 200-day simple moving average is $131.44.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.